News Feed Opinion Blog Posts Career Updates Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
August, 2025
August 2025
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031
Amol Akhade: Should CDK4/6 inhibitors be standard in early HR+/HER2– breast cancer?
Amol Akhade/hiranandanihospital.org
Apr 16, 2025, 17:55

Amol Akhade: Should CDK4/6 inhibitors be standard in early HR+/HER2– breast cancer?

Amol Akhade, Senior Medical and Hemato-Oncologist based in Mumbai, India, shared a post on LinkedIn:

“LET’S PLAY DEVIL’S ADVOCATE:

Should CDK4/6 inhibitors be standard in early HR+/HER2– breast cancer? Tannock et al. JCO_ASCO argue –

Modest iDFS, no OS benefit ( yet ) , high toxicity and censoring bias.

I broke it down—with counterarguments .

Do Check this out.”

Why We Do Not Recommend That Women With Breast Cancer Receive Adjuvant Treatment With a CDK4/6 Inhibitor

Authors: Ian F. Tannock, Qamar J. Khan, and Tito Fojo 

Amol Akhade: Should CDK4/6 inhibitors be standard in early HR+/HER2– breast cancer?

More posts featuring Amol Akhade.

Amol Akhade Breast Cancer cancer cancer treatment Ian F. Tannock OncoDaily Oncology Qamar J. Khan Tito Fojo
Special Coverage
Voices
Aug 21, 2025, 15:59
George Kumar: The interplay Between Cardiovascular Disease (CVD) and Cancer
Voices
Aug 21, 2025, 15:47
European Society of Gynaecological Oncology Announces that Applications are Open for Editor-in-Chief of IJGC
Insight
Aug 21, 2025, 15:37
Carolina Reduzzi: ctDNA Landscape Analysis Post CDK4/6 Inhibitor in HR+/HER2- Metastatic Breast Cancer
Voices
Aug 21, 2025, 15:30
Clinician-Scientists Awarded NMRC Transition Awards for Precision Lung Cancer Research - National Cancer Centre Singapore
Voices
Aug 21, 2025, 15:22
Construction of the $658 million Sydney Children’s Hospital Stage One and MCCCC Project Has Reached Completion
Oncolibrary
Aug 21, 2025, 15:00
Breakthrough Emactuzumab Phase 3 TANGENT Trial in TGCT: SynOx Pharma Reports Enrollment Completed Ahead of Schedule
Voices
Aug 21, 2025, 14:50
Andrea Apolo Highlights the Top 5 Clinical Advances in Bladder Cancer Treatment for 2024
Insight
Aug 21, 2025, 14:47
Loay Kassem: Study Reveals BRCA Mutation Rates in Egyptian Women with Breast or Ovarian Cancer
Insight
Aug 21, 2025, 14:41
Tiago Cordeiro Felismino: Exploring the Role of Neutrophil-to-Lymphocyte Ratio in Advanced HCC Treatment
Voices
Aug 21, 2025, 14:40
Larissa Nekhlyudov Celebrates Leadership of Emily Smith Tonorezos and Michelle Mollica in Cancer Survivorship
Voices
Aug 21, 2025, 14:32
Hayley Jones: McCabe Centre Supports Daffodil Day with 38,000 Daffodils for Cancer Awareness
Voices
Aug 21, 2025, 14:26
Chrystal Paulos: Exciting Opportunities to Build with the Paulos Lab at Winship Cancer Institute